Can a recombinant influenza vaccine better protect adults with severe obesity?
Source PublicationClinical Infectious Diseases
Primary AuthorsLoubet, Czernichow, Giboin et al.
"Imagine your immune system is a security team preparing for a winter storm. Both the standard egg-based vaccine and the recombinant influenza vaccine provide the team with a briefing on the incoming threat. However, the recombinant briefing prompts the guards to rally a significantly larger frontline defence force within the first month—exactly when the storm is most likely to hit."
How does the body find order in the elegance of biological chaos? When a virus invades, our immune system scrambles into a frenzy of activity, reading genetic codes and building targeted weapons. It is a messy, beautiful process of trial and error.
These results were observed under controlled laboratory conditions, so real-world performance may differ.
Evolution has shaped this defence mechanism over millions of years. However, when we introduce metabolic stress—like severe obesity—this ancient system can struggle. The biological environment changes in ways that can impair our natural responses to vaccination. For reasons we are still unravelling, severe obesity leaves individuals at an increased risk of severe complications from the flu, creating a vulnerability in an otherwise elegant biological defence network.
Testing the recombinant influenza vaccine
To help this vulnerable group, researchers in France set up a clinical trial. They wanted to test if a different type of jab could offer better protection than the usual options. For decades, the standard-dose influenza vaccines have been egg-based. But science is always looking for an edge, a way to refine our immunological tools.
Enter the recombinant influenza vaccine. The researchers designed a trial comparing this newer recombinant option against the standard egg-based dose to see if it might provide enhanced protection for this specific, high-risk population.
The trial measured the immune responses of 206 adults with a body mass index of 35 or higher. Half received the standard egg-based dose, and half received the recombinant version. After 28 days, the results were compelling. The recombinant jab produced a stronger humoral immune response—specifically, higher antibody levels—for three out of the four flu strains tested.
It is important to note the scope of what this study actually found. The researchers measured antibody levels in the blood for specific influenza strains, rather than tracking actual flu infection rates in the community. However, this early spike in antibodies suggests the recombinant vaccine could provide a stronger short-term defence during the peak of winter flu season.
Interestingly, the study also measured responses at the six-month mark. By day 180, antibody levels in both groups were about the same. The initial advantage faded over time. This suggests that while the recombinant option offers a strong early boost, the long-term memory of the immune system in individuals with severe obesity remains a challenge to overcome. Still, that initial spike might be exactly what is needed to survive the worst of the flu season.